vs
波士顿科学（BSX）与联合太平洋（UNP）财务数据对比。点击上方公司名可切换其他公司
联合太平洋的季度营收约是波士顿科学的1.2倍（$6.2B vs $5.2B），联合太平洋净利率更高（27.4% vs 25.7%，领先1.6%），波士顿科学同比增速更快（11.6% vs 3.2%），过去两年波士顿科学的营收复合增速更高（12.4% vs 1.7%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
联合太平洋是美国一级货运铁路运营商，共运营8300台机车，线路总长超5.18万公里，覆盖芝加哥、新奥尔良以西的23个美国州，是全美规模仅次于BNSF的第二大铁路企业。
BSX vs UNP — 直观对比
营收规模更大
UNP
是对方的1.2倍
$5.2B
营收增速更快
BSX
高出8.4%
3.2%
净利率更高
UNP
高出1.6%
25.7%
两年增速更快
BSX
近两年复合增速
1.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $6.2B |
| 净利润 | $1.3B | $1.7B |
| 毛利率 | 69.5% | — |
| 营业利润率 | — | 39.5% |
| 净利率 | 25.7% | 27.4% |
| 营收同比 | 11.6% | 3.2% |
| 净利润同比 | 99.0% | 4.6% |
| 每股收益（稀释后） | $0.90 | $2.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXUNP
| Q1 26 | $5.2B | $6.2B | ||
| Q4 25 | $5.3B | $6.1B | ||
| Q3 25 | $5.1B | $6.2B | ||
| Q2 25 | $5.1B | $6.2B | ||
| Q1 25 | $4.7B | $6.0B | ||
| Q4 24 | $4.6B | $6.1B | ||
| Q3 24 | $4.2B | $6.1B | ||
| Q2 24 | $4.1B | $6.0B |
净利润BSXUNP
| Q1 26 | $1.3B | $1.7B | ||
| Q4 25 | $670.0M | $1.8B | ||
| Q3 25 | $755.0M | $1.8B | ||
| Q2 25 | $795.0M | $1.9B | ||
| Q1 25 | $672.0M | $1.6B | ||
| Q4 24 | $563.0M | $1.8B | ||
| Q3 24 | $468.0M | $1.7B | ||
| Q2 24 | $322.0M | $1.7B |
毛利率BSXUNP
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
营业利润率BSXUNP
| Q1 26 | — | 39.5% | ||
| Q4 25 | 15.6% | 39.5% | ||
| Q3 25 | 20.7% | 40.8% | ||
| Q2 25 | 16.2% | 41.0% | ||
| Q1 25 | 19.8% | 39.3% | ||
| Q4 24 | 14.8% | 41.3% | ||
| Q3 24 | 17.4% | 39.7% | ||
| Q2 24 | 12.6% | 40.0% |
净利率BSXUNP
| Q1 26 | 25.7% | 27.4% | ||
| Q4 25 | 12.7% | 30.4% | ||
| Q3 25 | 14.9% | 28.6% | ||
| Q2 25 | 15.7% | 30.5% | ||
| Q1 25 | 14.4% | 27.0% | ||
| Q4 24 | 12.3% | 28.8% | ||
| Q3 24 | 11.1% | 27.4% | ||
| Q2 24 | 7.8% | 27.9% |
每股收益（稀释后）BSXUNP
| Q1 26 | $0.90 | $2.87 | ||
| Q4 25 | $0.45 | $3.12 | ||
| Q3 25 | $0.51 | $3.01 | ||
| Q2 25 | $0.53 | $3.15 | ||
| Q1 25 | $0.45 | $2.70 | ||
| Q4 24 | $0.38 | $2.91 | ||
| Q3 24 | $0.32 | $2.75 | ||
| Q2 24 | $0.22 | $2.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $735.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | — |
| 总资产 | — | $69.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BSXUNP
| Q1 26 | — | $735.0M | ||
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.3B | $808.0M | ||
| Q2 25 | $534.0M | $1.1B | ||
| Q1 25 | $725.0M | $1.4B | ||
| Q4 24 | $414.0M | $1.0B | ||
| Q3 24 | $2.5B | $947.0M | ||
| Q2 24 | $2.9B | $1.1B |
总债务BSXUNP
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $30.3B | ||
| Q3 25 | $11.1B | $30.3B | ||
| Q2 25 | $11.1B | $30.3B | ||
| Q1 25 | $10.5B | $30.6B | ||
| Q4 24 | $9.0B | $29.8B | ||
| Q3 24 | $9.2B | $29.8B | ||
| Q2 24 | $9.0B | $31.2B |
股东权益BSXUNP
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $18.5B | ||
| Q3 25 | $23.4B | $17.3B | ||
| Q2 25 | $22.4B | $16.3B | ||
| Q1 25 | $22.2B | $16.0B | ||
| Q4 24 | $21.8B | $16.9B | ||
| Q3 24 | $20.7B | $16.6B | ||
| Q2 24 | $20.4B | $16.5B |
总资产BSXUNP
| Q1 26 | — | $69.6B | ||
| Q4 25 | $43.7B | $69.7B | ||
| Q3 25 | $42.7B | $68.6B | ||
| Q2 25 | $41.6B | $68.6B | ||
| Q1 25 | $40.1B | $68.5B | ||
| Q4 24 | $39.4B | $67.7B | ||
| Q3 24 | $38.1B | $67.6B | ||
| Q2 24 | $37.1B | $67.8B |
负债/权益比BSXUNP
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 1.64× | ||
| Q3 25 | 0.48× | 1.75× | ||
| Q2 25 | 0.50× | 1.86× | ||
| Q1 25 | 0.47× | 1.91× | ||
| Q4 24 | 0.41× | 1.76× | ||
| Q3 24 | 0.45× | 1.79× | ||
| Q2 24 | 0.44× | 1.89× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $631.0M |
| 自由现金流率自由现金流/营收 | — | 10.1% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $4.8B |
8季度趋势，按日历期对齐
经营现金流BSXUNP
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $2.2B | ||
| Q3 25 | $1.3B | $2.5B | ||
| Q2 25 | $1.3B | $2.3B | ||
| Q1 25 | $541.0M | $2.2B | ||
| Q4 24 | $1.5B | $2.7B | ||
| Q3 24 | $1.0B | $2.7B | ||
| Q2 24 | $813.0M | $1.9B |
自由现金流BSXUNP
| Q1 26 | — | $631.0M | ||
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $1.2B | $1.6B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $354.0M | $1.3B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $823.0M | $1.8B | ||
| Q2 24 | $658.0M | $1.0B |
自由现金流率BSXUNP
| Q1 26 | — | 10.1% | ||
| Q4 25 | 19.2% | 20.1% | ||
| Q3 25 | 22.9% | 25.2% | ||
| Q2 25 | 22.3% | 22.7% | ||
| Q1 25 | 7.6% | 21.6% | ||
| Q4 24 | 25.8% | 28.4% | ||
| Q3 24 | 19.6% | 29.9% | ||
| Q2 24 | 16.0% | 16.8% |
资本支出强度BSXUNP
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 16.4% | ||
| Q3 25 | 3.6% | 15.2% | ||
| Q2 25 | 3.1% | 15.2% | ||
| Q1 25 | 4.0% | 15.0% | ||
| Q4 24 | 6.1% | 15.1% | ||
| Q3 24 | 4.3% | 13.6% | ||
| Q2 24 | 3.8% | 15.0% |
现金转化率BSXUNP
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 1.20× | ||
| Q3 25 | 1.78× | 1.41× | ||
| Q2 25 | 1.62× | 1.24× | ||
| Q1 25 | 0.81× | 1.36× | ||
| Q4 24 | 2.59× | 1.51× | ||
| Q3 24 | 2.14× | 1.59× | ||
| Q2 24 | 2.52× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
UNP
| Freight revenues | $5.9B | 95% |
| Other revenues | $324.0M | 5% |
